Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
LEHI, Utah, Sept. 9, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York City.
David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs on Wednesday, September 16, 2026, from 1:05-1:40 pm ET.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah, developing first-in-class therapies that target inflammasome-driven disease biology. The company focuses on addressing significant unmet needs in hematologic diseases through novel mechanisms designed to target the root causes of inflammation-driven pathology. Halia's lead program, ofirnoflast, is being developed for lower-risk MDS and other hematologic diseases driven by NLRP3 inflammasome biology. Its broader pipeline is grounded in human genetic resilience and precision medicine. For more information, visit www.haliatx.com.
Investor Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Media Contact
Taylor Avei, Head of Business Development
Halia Therapeutics
tavei@haliatx.com
SOURCE Halia Therapeutics
LEHI, Utah, Sept. 9, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York City.
David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs on Wednesday, September 16, 2026, from 1:05-1:40 pm ET.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah, developing first-in-class therapies that target inflammasome-driven disease biology. The company focuses on addressing significant unmet needs in hematologic diseases through novel mechanisms designed to target the root causes of inflammation-driven pathology. Halia's lead program, ofirnoflast, is being developed for lower-risk MDS and other hematologic diseases driven by NLRP3 inflammasome biology. Its broader pipeline is grounded in human genetic resilience and precision medicine. For more information, visit www.haliatx.com.
Investor Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Media Contact
Taylor Avei, Head of Business Development
Halia Therapeutics
tavei@haliatx.com
SOURCE Halia Therapeutics
حول هاليا ثيرابيوتك
Halia Therapeutics هي شركة أدوية بيولوجية في المرحلة السريرية تركز على علاج الأسباب الجذرية للالتهاب. من خلال الاستفادة من الرؤى الجينية والاكتشافات المدعومة بالذكاء الاصطناعي، تقوم Halia ببناء خط أنابيب قوي من العلاجات الجديدة القائمة على المرونة الجينية التي تستهدف المسارات الالتهابية في الأمراض التي تتراوح من الاضطرابات الأيضية إلى التنكّس العصبي والأورام الدموية الخبيثة.
تتمثل مهمة Halia في إنشاء علاجات تعتمد على البيانات لا تطيل العمر فحسب، بل تعمل أيضًا على تحسين جودتها. يقع المقر الرئيسي للشركة في ليهي بولاية يوتا، وتعمل بنشاط على تعزيز الشراكات العالمية في الأبحاث السريرية واكتشاف الأدوية والطب الشخصي.
لمعرفة المزيد، تفضل بزيارة www.haliatx.com أو تابعنا على لينكد إن وتويتر @HaliaTx.